{"url_path":"/sec/slxnw/8-k/2026-05-18/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002761-index.html","accession_number":"0001178913-26-002761","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002761-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":135,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operations and Financial Condition.\n\n \n\nOn May 18, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the first\nquarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02.\n\n \n\nThe information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the\npurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section,\nnor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as may be expressly set forth by specific reference in such filing."}